Goudsmit Ben F J, Braat Andries E, Tushuizen Maarten E, Coenraad Minneke J, Vogelaar Serge, Alwayn Ian P J, van Hoek Bart, Putter Hein
Department of Gastroenterology and Hepatology, Leiden University Medical Center, The Netherlands.
Eurotransplant International Foundation, Leiden, The Netherlands.
JHEP Rep. 2021 Sep 29;3(6):100369. doi: 10.1016/j.jhepr.2021.100369. eCollection 2021 Dec.
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is usually associated with a precipitating event and results in the failure of other organ systems and high short-term mortality. Current prediction models fail to adequately estimate prognosis and need for liver transplantation (LT) in ACLF. This study develops and validates a dynamic prediction model for patients with ACLF that uses both longitudinal and survival data.
Adult patients on the UNOS waitlist for LT between 11.01.2016-31.12.2019 were included. Repeated model for end-stage liver disease-sodium (MELD-Na) measurements were jointly modelled with Cox survival analysis to develop the ACLF joint model (ACLF-JM). Model validation was carried out using separate testing data with area under curve (AUC) and prediction errors. An online ACLF-JM tool was created for clinical application.
In total, 30,533 patients were included. ACLF grade 1 to 3 was present in 16.4%, 10.4% and 6.2% of patients, respectively. The ACLF-JM predicted survival significantly ( <0.001) better than the MELD-Na score, both at baseline and during follow-up. For 28- and 90-day predictions, ACLF-JM AUCs ranged between 0.840-0.871 and 0.833-875, respectively. Compared to MELD-Na, AUCs and prediction errors were improved by 23.1%-62.0% and 5%-37.6% respectively. Also, the ACLF-JM could have prioritized patients with relatively low MELD-Na scores but with a 4-fold higher rate of waiting list mortality.
The ACLF-JM dynamically predicts outcome based on current and past disease severity. Prediction performance is excellent over time, even in patients with ACLF-3. Therefore, the ACLF-JM could be used as a clinical tool in the evaluation of prognosis and treatment in patients with ACLF.
Acute-on-chronic liver failure (ACLF) progresses rapidly and often leads to death. Liver transplantation is used as a treatment and the sickest patients are treated first. In this study, we develop a model that predicts survival in ACLF and we show that the newly developed model performs better than the currently used model for ranking patients on the liver transplant waiting list.
慢加急性肝衰竭(ACLF)通常与诱发事件相关,会导致其他器官系统功能衰竭,短期死亡率高。目前的预测模型无法充分评估ACLF患者的预后及肝移植(LT)需求。本研究开发并验证了一种针对ACLF患者的动态预测模型,该模型同时使用纵向数据和生存数据。
纳入2016年1月11日至2019年12月31日在UNOS等待LT的成年患者。将终末期肝病钠(MELD-Na)测量值的重复模型与Cox生存分析联合建模,以开发ACLF联合模型(ACLF-JM)。使用具有曲线下面积(AUC)和预测误差的单独测试数据进行模型验证。创建了一个在线ACLF-JM工具用于临床应用。
共纳入30533例患者。ACLF 1至3级患者分别占16.4%、10.4%和6.2%。ACLF-JM在基线期和随访期间对生存的预测均显著优于MELD-Na评分(<0.001)。对于28天和90天的预测,ACLF-JM的AUC分别在0.840 - 0.871和0.833 - 0.875之间。与MELD-Na相比,AUC和预测误差分别提高了23.1% - 62.0%和5% - 37.6%。此外,ACLF-JM可以对MELD-Na评分相对较低但等待名单死亡率高4倍的患者进行优先排序。
ACLF-JM基于当前和过去的疾病严重程度动态预测预后。随着时间推移,预测性能优异,即使对于ACLF-3患者也是如此。因此,ACLF-JM可作为评估ACLF患者预后和治疗的临床工具。
慢加急性肝衰竭(ACLF)进展迅速,常导致死亡。肝移植是一种治疗方法,病情最严重的患者优先接受治疗。在本研究中,我们开发了一种预测ACLF患者生存的模型,并且表明新开发的模型在对肝移植等待名单上的患者进行排序方面比目前使用的模型表现更好。